Biotech: Page
-
Courtesy of CureVac
CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement
The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.
By Jonathan Gardner • July 5, 2022 -
Christopher Furlong via Getty Images
With $100M AstraZeneca deal, a biotech and its investors engineer another buyout
An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.
By Ben Fidler • July 5, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Kena Betancur via Getty Images
Crunching the numbers on the first half drought for biotech IPOs
Data compiled by BioPharma Dive show a growing gap in the frequency and size of new offerings compared to prior years. Some analysts believe as many as a third of public biotechs must “go away” before the sector’s slump ends.
By Ben Fidler • July 1, 2022 -
Getty Images
Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.
By Delilah Alvarado • June 29, 2022 -
Arch brings in another $3B for biotech startup investing
The venture firm’s largest-ever haul comes about a year and a half after it raised another $2 billion and amidst an historic downturn for the sector.
By Jacob Bell • June 29, 2022 -
Permission granted by Relay Therapeutics
Relay details new research plans in quest to design better cancer drugs
The biotech company revealed three new drug candidates for breast cancer, while laying out a path to regulators for its most advanced treatment.
By Ned Pagliarulo • June 27, 2022 -
Permission granted by Biogen
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.
By Jacob Bell • June 22, 2022 -
Courtesy of Galapagos
Galapagos, with latest deals, charts an unexpected journey to cell therapy
The Belgian drugmaker will spend more than $100 million to acquire two companies, CellPoint and AboundBio, in a move meant to “disrupt” CAR-T treatment.
By Jacob Bell • June 22, 2022 -
Getty / Edited by BioPharma Dive
A biotech startup launches with $38M to develop a cystic fibrosis gene therapy
Carbon Biosciences believes its technology, which is based on parvoviruses, could allow for larger gene delivery and repeat dosing.
By Delilah Alvarado • June 21, 2022 -
Getty Images
Boehringer extends cancer dealmaking with right to buy biotech partner
The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer.
By Delilah Alvarado • June 16, 2022 -
Spencer Platt via Getty Images
With biotech in retreat, Third Rock raises $1B for life sciences investing
The fund, Third Rock’s sixth, comes amid a significant downturn in biotech stocks, which has raised questions about the viability of young drug startups.
By Jacob Bell • June 15, 2022 -
Getty Images
Vertex, CRISPR strengthen case for pioneering gene-editing treatment
Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.
By Jacob Bell • June 11, 2022 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
GSK claims first positive Phase 3 result for an RSV vaccine
The British drugmaker now plans to seek approval of what could be the first preventive shot for the common lung infection. However, Pfizer, Johnson & Johnson and Moderna are close behind.
By Jonathan Gardner • June 10, 2022 -
Kena Betancur via Getty Images
Forbion raises $500M to back growing biotechs amid industry slump
The European venture firm’s latest fund will open up a new source of investment at a time companies are struggling to go public or hold their value.
By Delilah Alvarado • June 10, 2022 -
Alnylam follows rivals with new study results for kidney disease drug
An experimental medicine the company is developing with Regeneron has shown early promise treating IgA nephropathy, a disease that’s become a competitive target among drugmakers.
By Jonathan Gardner • June 9, 2022 -
Courtesy of Novavax, Australian Broadcasting Corporation
FDA advisers back Novavax's latecomer COVID-19 vaccine
Outside experts debated the shot's safety profile and its efficacy versus the omicron variant but ultimately supported the vaccine, which is made using more traditional technology than Pfizer's and Moderna's.
By Jonathan Gardner • Updated June 7, 2022 -
Biotech Athersys to lay off 70% of staff in cost-cutting effort
The stem cell therapy company said the restructuring is meant as a first step toward making it "more attractive" to potential financial and strategic partners.
By Delilah Alvarado • June 6, 2022 -
Getty Images
FDA extends review of Amylyx ALS drug, delaying approval decision
The agency said it wanted more time to assess additional clinical trial data submitted by Amylyx, and set a new decision date of Sept. 29 for the closely watched treatment.
By Ned Pagliarulo • June 3, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
While priced at a significant premium, the deal values Turning Point well below its peak valuation last year, a potential sign biotechs might be adjusting their expectations amid the sector's downturn.
By Jonathan Gardner • Updated June 3, 2022 -
Permission granted by Roche
Roche gambles $125M on a sliding biotech's cancer drug
Months after early results from Repare Therapeutics' drug disappointed analysts, the Swiss pharma has acquired rights, betting it may prove useful in combinations with other treatments.
By Kristin Jensen • June 2, 2022 -
Permission granted by Tessera Therapeutics
Former AbbVie executive Severino joins Flagship-backed startup as CEO
Severino left the pharma company in April after eight years as its chief scientist and then president. He'll lead Tessera Therapeutics, a well-funded genetic medicine startup.
By Ned Pagliarulo • June 2, 2022 -
Permission granted by Upstream Bio
Upstream Bio, a richly funded startup, reveals its lead drug and research plans
Backed by $200 million in funding and led by biotech veteran Samantha Truex, Upstream is developing a clinical-stage inflammatory disease drug acquired from Astellas last year.
By Ned Pagliarulo • June 2, 2022 -
Permission granted by Biogen
Sage, Biogen drug meets goal in postpartum depression study
The results will help support an application for FDA approval, which the companies plan to submit early next year. They are already seeking an OK for their treatment in major depressive disorder.
By Ned Pagliarulo • June 1, 2022 -
Sarah Silbiger via Getty Images
BioMarin delays planned FDA filing for hemophilia gene therapy
The California biotech now expects to resubmit its approval application to the FDA by the end of September, the latest regulatory setback for its closely watched treatment.
By Ned Pagliarulo • May 31, 2022 -
Retrieved from National Cancer Institute on September 27, 2019
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
Fresh study results showed similar rates of response and progression-free survival with Mirati's experimental adragasib as with Amgen's approved Lumakras. The new data might raise safety questions, however.
By Ned Pagliarulo • Updated May 27, 2022
Previous
